A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease

A Dose-Finding Study To Compare The Safety, Tolerability, And Efficacy Of Differing Dosing Regimens Of ISV-101 (Bromfenac In DuraSite® Ophthalmic Solution) To Vehicle And DuraSite Alone In Dry Eye Disease Volunteers

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01478555

Acronym

ISV-101

Enrollment

Registered

2011-11-23

Start date

2018-01-31

Completion date

2019-01-31

Last updated

2021-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Disease

Keywords

Dry Eye

Brief summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-101 (Bromfenac in DuraSite® ophthalmic solution) compared to Vehicle and DuraSite alone.

Interventions

DRUGISV 101

Bromfenac in DuraSite

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Volunteers 18 years of age and older who have a diagnosis of moderate to severe dry eye disease. 2. Negative pregnancy test prior to the conduct of any protocol-specific procedure. The subject must use effective contraception for the duration of the study. Post menopausal is defined as having no menses for at least 12 consecutive months 3. Signature of the subject on the Informed Consent Form 4. Willing to avoid disallowed medication for the duration of the study. 5. Able to self-administer study drug (or have a caregiver available to instill all doses of study drug) 6. Able and willing to follow study instructions 7. Additional inclusion criteria also apply

Exclusion criteria

1. Females who are pregnant or nursing. Females of childbearing potential (not surgically sterilized or postmenopausal) may not participate in the study if they do not agree to use adequate birth control methods for the duration of the study). 2. Use of contact lenses during the study. 3. Use of any concomitant topical ocular medications except for artificial tears during the dosing period 4. Presence or history of treatment with systemic immunosuppressive or chemotherapeutic agents. 5. Prior or anticipated concurrent use of an investigational product or device that could confound the findings about Dry Eye in the study eye. 6. A condition or a situation, which in the investigator's opinion may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation 7. Known hypersensitivity to any component of the study drug or procedural medications 8. Participation in any other clinical trial within 30 days prior to screening 9. Known hypersensitivity to NSAIDS 10. Any active corneal epithelial/stromal pathology noted in the study eye at the screening visit 11. Any history of corneal surgery (including corneal crosslinking, radial keratotomy, corneal transplant, or LASIK) 12. Cataract surgery within the past year. 13. Known contraindication to the study drugs or any of their components

Design outcomes

Primary

Measure	Time frame
Improvement in Corneal Fluorescein Staining	Week 8
Improvement in OSDI Scoring	Week 8

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026